Hepatic Vascular Malformation Mimics PSMA-Positive Prostate Cancer Metastasis.
Aged, 80 and over
Androgen Antagonists
/ therapeutic use
Antigens, Surface
/ metabolism
Diagnosis, Differential
Glutamate Carboxypeptidase II
/ metabolism
Humans
Liver
/ blood supply
Liver Neoplasms
/ secondary
Male
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms
/ complications
Vascular Malformations
/ complications
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
26
4
2020
medline:
12
9
2020
entrez:
26
4
2020
Statut:
ppublish
Résumé
An 80-year-old man developed high-risk prostate cancer after 7 years of active surveillance. For staging and treatment planning, a Ga-PSMA PET/MRI was performed. Besides the PSMA-positive primary tumor and a solitary bone metastasis in the fifth thoracic vertebral body, an intensive intrahepatic PSMA expression (SUVmax, 16.3) was suspicious for a liver metastasis. The results of a previously performed contrast-enhanced CT, a consecutively performed contrast-enhanced ultrasound, and a follow-up PSMA PET/CT after 4 months with a stable lesion during androgen deprivation lead to the diagnosis of a vascular malformation metabolically mimicking a hepatic metastasis of the prostate tumor.
Identifiants
pubmed: 32332316
doi: 10.1097/RLU.0000000000003032
pii: 00003072-202006000-00036
doi:
Substances chimiques
Androgen Antagonists
0
Antigens, Surface
0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e283-e284Références
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–629.
Stavrinides V, Parker CC, Moore CM. When no treatment is the best treatment: active surveillance strategies for low risk prostate cancers. Cancer Treat Rev. 2017;58:14–21.
Damjanovic J, Janssen JC, Prasad V, et al. 68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer. Cancer Imaging. 2019;19:37.
Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–583.
Ajiboye N, Chalouhi N, Starke RM, et al. Cerebral arteriovenous malformations: evaluation and management. ScientificWorldJournal. 2014;2014:649036.
Schwenck J, Rempp H, Reischl G, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017;44:92–101.
Sheikhbahaei S, Werner RA, Solnes LB, et al. Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls. Semin Nucl Med. 2019;49:255–270.
Osmany S, Zaheer S, Bartel TB, et al. Gallium-68-labeled prostate-specific membrane antigen-11 PET/CT of prostate and nonprostate cancers. AJR Am J Roentgenol. 2019;213:286–299.
Salas Fragomeni RA, Amir T, Sheikhbahaei S, et al. Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. J Nucl Med. 2018;59:871–877.
Jiao D, Li Y, Yang F, et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma. Clin Transl Gastroenterol. 2019;10:1–7.
Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–2681.
Bhardwaj H, Stephens M, Bhatt M, et al. Prostate-specific membrane antigen PET/CT findings for hepatic hemangioma. Clin Nucl Med. 2016;41:968–969.